RE:RE:RE:RE:RE:RE:0.27 its not like we have investment analyst reports to look at and comment on. the last half decent analysis was from seeking alpha many moons ago.
one can only presume that some research was at least done with industry or consultant experts when coming up with numbers.
I have spoken with some industry people myself and royalties typically range from 4 to 12%, and if a top 10 is involved then the growth and market share could be feasible over time at least in pharma sector at global proportions. As for the upfront payment, that I can't really comment on. But if an upfront payment is decent it can compensate for the time the partner needs to ramp up and get product in hands. It is widely known this can take 12 months if moving quickly and believe that was approx the time for R&F. So this at least provided a basis to us to do our own due diligence.